(REPL) Replimune - Performance 10.7% in 12m
REPL performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
-61.09%
#87 in Peer-Group
Rel. Strength
55.16%
#3452 in Stock-Universe
Total Return 12m
10.66%
#57 in Peer-Group
Total Return 5y
-57.83%
#69 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | - |
| P/E Forward | - |
| High / Low | USD |
|---|---|
| 52 Week High | 14.93 USD |
| 52 Week Low | 6.92 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 41.20 |
| Buy/Sell Signal +-5 | -1.56 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: REPL (10.7%) vs XBI (-9.1%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
-1.02% | 69.7% | 77.8% | 23.5 | 14.1 | 0.23 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
-10.4% | -7.09% | 151% | 11.3 | 10.5 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
2.42% | -1.57% | 39.4% | 27.2 | 14.2 | 0.99 | 0.60% | 41% |
| BIM PA Biomerieux |
-1.65% | 30.3% | -1.81% | 32.7 | 25.8 | 1.55 | -38.5% | -25.1% |
| NBIX NASDAQ Neurocrine Biosciences |
2.39% | -9.49% | -0.73% | 43 | 24.8 | 0.27 | 18.7% | -34.3% |
| KMDA NASDAQ Kamada |
10.5% | 38.7% | -6.49% | 27.6 | 22.4 | 0.9 | 68.9% | 36.8% |
| PTCT NASDAQ PTC Therapeutics |
-7.82% | 50.2% | -13.3% | 7.54 | 6.09 | 0.81 | - | 68% |
| ERF PA Eurofins Scientific SE |
1.95% | 29.1% | 18.3% | 28.9 | 15.4 | 0.64 | -62.1% | -19.3% |
Performance Comparison: REPL vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for REPL
| Total Return (including Dividends) | REPL | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -8.25% | 0.53% | 3.75% |
| 3 Months | 30.81% | 21.37% | 25.32% |
| 12 Months | 10.66% | -9.11% | 13.11% |
| 5 Years | -57.83% | -25.99% | 109.78% |
| Trend Score (consistency of price movement) | REPL | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -70.2% | -5.7% | 80.3% |
| 3 Months | 59.1% | 79.4% | 97.2% |
| 12 Months | -27.2% | -86.9% | 45.4% |
| 5 Years | -84.4% | -52.2% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th33.00 | -8.74% | -11.57% |
| 3 Month | %th58.00 | 7.78% | 4.38% |
| 12 Month | %th72.50 | 21.75% | -2.16% |
| 5 Years | %th67.00 | -43.02% | -79.90% |
FAQs
Does Replimune (REPL) outperform the market?
Yes,
over the last 12 months REPL made 10.66%, while its related Sector, the SPDR S&P Biotech (XBI) made -9.11%.
Over the last 3 months REPL made 30.81%, while XBI made 21.37%.
Performance Comparison REPL vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
REPL vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 1.6% | -12% | -24.9% | -2% |
| US NASDAQ 100 | QQQ | 1.1% | -12.4% | -26.5% | -1% |
| German DAX 40 | DAX | -0.2% | -8.5% | -37.6% | -20% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 0.6% | -12% | -28.6% | -11% |
| Hongkong Hang Seng | HSI | 2.1% | -11.3% | -45.3% | -28% |
| India NIFTY 50 | INDA | 2.4% | -9.1% | -25.4% | 12% |
| Brasil Bovespa | EWZ | 2.4% | -14.1% | -46.9% | 3% |
REPL vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 3% | -11.8% | -29.4% | -13% |
| Consumer Discretionary | XLY | 2.4% | -10.2% | -17.1% | -5% |
| Consumer Staples | XLP | 2.9% | -8.7% | -25.4% | 3% |
| Energy | XLE | -1.5% | -15% | -21.1% | 9% |
| Financial | XLF | 2.9% | -11% | -27.4% | -17% |
| Health Care | XLV | 3.4% | -9.3% | -15.9% | 16% |
| Industrial | XLI | 1.5% | -11.4% | -31.8% | -14% |
| Materials | XLB | 0.8% | -12% | -28.5% | 5% |
| Real Estate | XLRE | 2.8% | -8.1% | -23.8% | -1% |
| Technology | XLK | -0% | -15.4% | -29% | 1% |
| Utilities | XLU | 3.1% | -9.5% | -27.2% | -11% |
| Aerospace & Defense | XAR | 0.9% | -12% | -43% | -37% |
| Biotech | XBI | 0.1% | -8.8% | -10.8% | 20% |
| Homebuilder | XHB | 2.9% | -14.3% | -17% | 7% |
| Retail | XRT | 1.6% | -9.8% | -20.2% | 1% |
REPL vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | -2% | -15.1% | -18.6% | 15% |
| Natural Gas | UNG | 3.9% | 2.2% | -5.7% | 17% |
| Gold | GLD | 3.2% | -7.5% | -42.7% | -29% |
| Silver | SLV | 0.4% | -8% | -40.5% | -8% |
| Copper | CPER | -4.9% | -18.3% | -45.3% | -8% |
REPL vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | 4.5% | -9.3% | -21.2% | 14% |
| iShares High Yield Corp. Bond | HYG | 2.3% | -9.6% | -23.3% | 1% |